Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to identifying, developing, and commercializing life-changing medicines for people with serious diseases, often with limited or no therapeutic options. The company's mission is to innovate to transform the lives of patients and their families. Headquartered in Dublin, Ireland, Jazz Pharmaceuticals focuses on addressing significant unmet medical needs worldwide.

The company's diverse portfolio of marketed medicines primarily targets neuroscience and oncology. Key neuroscience products include Xywav and Xyrem for narcolepsy and idiopathic hypersomnia, and Epidiolex for severe forms of epilepsy such as Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex. In oncology, Jazz Pharmaceuticals offers Zepzelca for metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, Vyxeos for acute myeloid leukemia, and Ziihera for HER2-positive biliary tract cancer. The company also has Modeyso (dordaviprone) in its portfolio for H3 K27M-mutant diffuse glioma.

Under the leadership of President and CEO Renée Galá, Jazz Pharmaceuticals continues to advance its pipeline and market presence. Recent notable developments include the FDA's acceptance with Priority Review for Ziihera (zanidatamab-hrii) combinations as a first-line therapy for HER2-positive unresectable locally advanced or metastatic gastric, GEJ, or gastroesophageal adenocarcinoma, with a PDUFA target action date of August 25, 2026. The company reported record total revenue of $4.3 billion in 2025, driven by strong performance from key products like Xywav and Epidiolex, reinforcing its position as a specialist innovator in areas of high unmet medical need.

Latest updates

Jazz Pharmaceuticals Secures Priority FDA Review for Ziihera GEA Combination

Event summary

  • Jazz Pharmaceuticals received FDA acceptance for a supplemental Biologics License Application (sBLA) for Ziihera® (zanidatamab-hrii) in combination therapies for first-line treatment of HER2+ GEA.
  • The FDA has assigned a Priority Review designation and a PDUFA target action date of August 25, 2026.
  • The submission is based on data from the Phase 3 HERIZON-GEA-01 trial, which demonstrated efficacy with or without Tevimbra® (tislelizumab).
  • The FDA granted Breakthrough Therapy Designation for the zanidatamab combination therapy.

The big picture

The approval of Ziihera in this indication represents a significant advancement in the treatment of HER2+ GEA, a cancer with a historically poor prognosis and limited therapeutic options. The combination with tislelizumab, demonstrating efficacy across both PD-L1 positive and negative tumors, addresses a key unmet need. Jazz's partnership with BeOne Medicines and licensing from Zymeworks highlights the increasing complexity of oncology drug development and the reliance on external innovation.

What we're watching

Clinical Data
The full HERIZON-GEA-01 trial data, beyond the topline results, will be crucial in understanding the magnitude of benefit and identifying patient populations most likely to respond to the combination therapy.
Regulatory Risk
While the Priority Review and Breakthrough Therapy designation expedite the process, the FDA’s Real-Time Oncology Review program doesn’t guarantee approval, and potential safety concerns could still lead to rejection or restrictions.
Market Adoption
The success of Ziihera will depend on physician adoption and patient access, which will be influenced by pricing, reimbursement, and competition from existing and emerging HER2-targeted therapies.
CID: 2328